Antares Pharma (NASDAQ:ATRS) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Tuesday, ValuEngine reports.

Separately, BidaskClub raised shares of Antares Pharma from a “buy” rating to a “strong-buy” rating in a report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $4.05.

NASDAQ ATRS opened at $4.95 on Tuesday. Antares Pharma has a 52 week low of $2.53 and a 52 week high of $5.06. The company has a quick ratio of 2.46, a current ratio of 2.95 and a debt-to-equity ratio of 1.00. The company has a market capitalization of $772.06 million, a P/E ratio of -123.75 and a beta of 0.91. The stock’s 50-day moving average price is $3.93 and its 200-day moving average price is $3.36.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings data on Tuesday, November 5th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.03. The company had revenue of $34.31 million during the quarter, compared to the consensus estimate of $26.36 million. Antares Pharma had a negative return on equity of 1.40% and a negative net margin of 0.56%. Research analysts anticipate that Antares Pharma will post -0.04 EPS for the current year.

A number of institutional investors have recently modified their holdings of the stock. Bank of Montreal Can bought a new position in Antares Pharma in the 2nd quarter worth approximately $45,000. Aperio Group LLC bought a new stake in shares of Antares Pharma during the second quarter valued at approximately $47,000. Millennium Management LLC bought a new stake in shares of Antares Pharma during the third quarter valued at approximately $48,000. Alpine Woods Capital Investors LLC lifted its holdings in shares of Antares Pharma by 60.0% in the second quarter. Alpine Woods Capital Investors LLC now owns 16,000 shares of the specialty pharmaceutical company’s stock worth $53,000 after buying an additional 6,000 shares in the last quarter. Finally, Prudential Financial Inc. lifted its holdings in shares of Antares Pharma by 33.8% in the second quarter. Prudential Financial Inc. now owns 18,530 shares of the specialty pharmaceutical company’s stock worth $61,000 after buying an additional 4,680 shares in the last quarter. 38.62% of the stock is owned by institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Featured Story: Market Perform

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.